Flutemetamol, currently in phase III development, is being studied to identify the uptake of beta amyloid via imaging of the brain tissue in live humans.
The agent may help physicians detect amyloid deposition and assist in the detection and treatment of AD.
GE Healthcare Medical Diagnostics MI PET Segment leader Jonathan Allis said the ability to make visual assessments of amyloid in AD patients may enable physicians to seek earlier, confirmed diagnosis of AD and make more informed care decisions.
GE Healthcare Medical Diagnostics CEO Pascale Witz said at GE Healthcare, their scientists and researchers remain fully committed to developing enhanced diagnostics tools that may help Alzheimer’s Disease patients and their families get accurate information as early as possible.
